TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01315691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amikacin for inhalation
Description: * Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered for 28 days followed by 56 days off treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for liposomal amikacin for inhalation
Description: * Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~* Administration procedures, volume and administration time are the same as for Arikace™.~* Placebo will be administered for 28 days.
Study: NCT05447091

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LOH game- high dose
Description: Participants will be asked to complete 15 half-hour training sessions, over 3 weeks, ie about 5 training sessions a week, and a total of 7.5 hours of training for 3 weeks.
Study: NCT06197360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Based on BCW Theory of Health Education
Description: Questionnaire collection, face-to-face interview, and interpretation of the manual on the first day of admission; diabetes self-management teaching on the second day; and hypoglycemia-related lectures and hands-on teaching on the fourth day. Day 6 hypoglycemia fear case discussion. Face-to-face teaching and formulation of blood glucose management plan on the first day before discharge; WeChat push or telephone return visit one week and two weeks after discharge; WeChat push, telephone return visit and questionnaire collection three weeks after discharge.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General diabetes health education
Description: Patients were provided with regular medication guidance, dietary guidance, exercise guidance and popularization of related diabetes knowledge; regular daily blood glucose testing and recording; and timely answers to patients' clinical problems and psychological support.
Study: NCT05447091

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LOH game- low dose
Description: Participants will be asked to complete 6 half-hour training sessions, over 3 weeks, ie about 2 training sessions a week, and a total of 3 hours of training for 3 weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: LOH sham game
Description: Participants will be asked to complete 15 half-hour training sessions, over three weeks, using sham version of the game. the sham version does not include components of cognitive training.
Study: NCT05789368

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sachet
Description: consume 1 sachet per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VeCollal sachet
Description: consume 1 sachet per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Collagen sachet
Description: consume 1 sachet per day
Study: NCT04865133

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical record reviewed
Study: NCT05677919

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood, tissue, stool, and saliva samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study: NCT06251284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline nasal spray
Description: A saline nasal spray will be introduced as saline on the first day (no induced expectations) and as oxytocin on the second day (induced positive expectations)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline nasal spray
Description: A saline nasal spray will be introduced as saline on the first day (no induced expectations) and as oxytocin on the second day (induced positive expectations)
Study: NCT06409000

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records reviewed

Intervention type: PROCEDURE
Intervention: Three-Dimensional Imaging
Description: Undergo 3D surface scans
Study: NCT05923749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biatain Ag
Description: Biatain with silver

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cutimed Siltec Sorbact
Description: comparator device
Study: NCT06027671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group SPARCS Intervention
Description: Each session will be led by two trained individuals: a peer (history of criminal justice involvement and living with HIV) and a social worker.30 Within 14 days of release, participants will have one-on-one contact with a facilitator to update locator information, continue rapport building, review disclosure plans, provide a reminder of SPARCS logistics, and assign or remind the participant to a SPARCS group based on their location of residence and timing of release (depending on whether this occurred pre-release). Each Group-SPARCS meeting lasts approximately 2 hours, and the sessions occur in a private space in a community venue (e.g., community centre or church).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group SPARCS Intervention
Description: Each session will be led by two trained individuals: a peer (history of criminal justice involvement and living with HIV) and a social worker.30 Within 14 days of release, participants will have one-on-one contact with a facilitator to update locator information, continue rapport building, review disclosure plans, provide a reminder of SPARCS logistics, and assign or remind the participant to a SPARCS group based on their location of residence and timing of release (depending on whether this occurred pre-release). Each Group-SPARCS meeting lasts approximately 2 hours, and the sessions occur in a private space in a community venue (e.g., community centre or church).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ART-SPARCS Intervention
Description: ART will be provided every two months from correctional facility release to 6 months post-release (months 2, 4, and 6). Participants with less than two months of ART at release will receive a top-off to reach two months. ART will be pre-packaged by the DoH home clinic, collected by the facilitators, and distributed to the participants. At the time of distribution, the facilitators will conduct a standard DoH differentiated care symptom screen. Participants who report specific symptoms will be referred to the home clinic for further assessment per routine with Community Adherence Clubs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ART-SPARCS Intervention
Description: ART will be provided every two months from correctional facility release to 6 months post-release (months 2, 4, and 6). Participants with less than two months of ART at release will receive a top-off to reach two months. ART will be pre-packaged by the DoH home clinic, collected by the facilitators, and distributed to the participants. At the time of distribution, the facilitators will conduct a standard DoH differentiated care symptom screen. Participants who report specific symptoms will be referred to the home clinic for further assessment per routine with Community Adherence Clubs.
Study: NCT05038163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Facts
Description: The nutritional information label for each beverage is enlarged.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Warning
Description: The health risks of sugary beverages are communicated to subjects using words/text and simple images.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graphic Warning
Description: The health risks of sugary beverages are communicated to subjects using a combination of words/text and graphic images/photographs.
Study: NCT06205485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 400 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/m2 or 130 mg/m2 on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoruracil
Description: bolus fluoruracil (optional) 400 mg, infusional fluorouracil 2,400 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoruracil
Description: bolus fluoruracil (optional) 400 mg, infusional fluorouracil 2,400 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1,000 mg/m2 twice daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1,000 mg/m2 twice daily for 14 days

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: 54 Gy (27-30 fractions)
Study: NCT05215665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMOX Regimen
Description: Oxaliplatin 100mg/m2 IV d1 Q3W+ gemcitabine 1000mg/m2 IV d1/8 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMOX Regimen
Description: Oxaliplatin 100mg/m2 IV d1 Q3W+ gemcitabine 1000mg/m2 IV d1/8 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 8/12mg PO QD continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg IV d1 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg IV d1 Q3W
Study: NCT05384938

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Benralizumab
Description: Prospective, Single-arm Study to Assess the Safety of Fasenra® (Benralizumab) in Adult Patients of Severe Asthma with Eosinophilic Phenotype in India
Study: NCT04869358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab 20 mg s.c. on days 1, 7, 14, week 4 and every 4 weeks thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab 20 mg s.c. on days 1, 7, 14, week 4 and every 4 weeks thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab 20 mg s.c. on days 1, 7, 14, week 4 and every 4 weeks thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab 20 mg s.c. on days 1, 7, 14, week 4 and every 4 weeks thereafter
Study: NCT04806373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cathflo Activase
Description: Cathflo Activase 4mg in 50ml normal saline given through chest pleural catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talc Slurry Pleurodesis
Description: Talc, 5 gm in 50 ml Normal Saline given through chest pleural catheter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Talc Slurry Pleurodesis
Description: Talc, 5 gm in 50 ml Normal Saline given through chest pleural catheter
Study: NCT06036706

Intervention type: RADIATION
Group type: OTHER
Intervention: Normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning
Description: Patients receiving normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning (IMRT, VMAT, Tomotherapy...)

Intervention type: RADIATION
Group type: OTHER
Intervention: Hypo-fractionated stereotactic brain irradiation
Description: Patients receiving hypo-fractionated stereotactic brain irradiation

Intervention type: RADIATION
Group type: OTHER
Intervention: Normo-fractionated proton therapy brain irradiation
Description: Patients receiving normo-fractionated proton therapy brain irradiation

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive assessment by a trained neuropsychologis
Description: Participants without any meningioma, cancer history or neurological comorbidities will undergo cognitive assessment by a trained neuropsychologist, similarly as for patients
Study: NCT06560151

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3.75 µg H5N8 antigen plus full dose AS03A
Description: Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7.5 µg H5N8 antigen plus full dose AS03A
Description: Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 µg H5N8 antigen plus full dose AS03A
Description: Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3.75 µg H5N8 antigen plus half dose AS03A
Description: Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7.5 µg H5N8 antigen plus half dose AS03A
Description: Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 µg H5N8 antigen plus half dose AS03A
Description: Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N8 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3.75 µg H5N8 antigen plus MF59
Description: Two intramuscular doses (21 days apart) of MF59 adjuvanted H5N8 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3.75 µg H5N8 antigen plus MF59
Description: Two intramuscular doses (21 days apart) of MF59 adjuvanted H5N8 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7.5 µg H5N8 antigen plus MF59
Description: Two intramuscular doses (21 days apart) of MF59 adjuvanted H5N8 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7.5 µg H5N8 antigen plus MF59
Description: Two intramuscular doses (21 days apart) of MF59 adjuvanted H5N8 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 µg H5N8 antigen plus MF59
Description: Two intramuscular doses (21 days apart) of MF59 adjuvanted H5N8 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 µg H5N8 antigen plus MF59
Description: Two intramuscular doses (21 days apart) of MF59 adjuvanted H5N8 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3.75 µg H5N1 antigen plus full dose AS03A
Description: Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N1 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7.5 µg H5N1 antigen plus full dose AS03A
Description: Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N1 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 µg H5N1 antigen plus full dose AS03A
Description: Two intramuscular doses (21 days apart) of AS03A adjuvanted H5N1 vaccine.
Study: NCT06478342

Intervention type: PROCEDURE
Intervention: ablation
Description: Pulsed field ablation, MRI and TEE examinations (LA strain)
Study: NCT06244992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTT-936
Description: Eligible patients will receive single-agent PTT-936 administered per orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTT-936
Description: Eligible patients will receive single-agent PTT-936 administered per orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTT-936
Description: Eligible patients will receive single-agent PTT-936 administered per orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTT-936
Description: Eligible patients will receive single-agent PTT-936 administered per orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTT-936
Description: Eligible patients will receive single-agent PTT-936 administered per orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTT-936
Description: Eligible patients will receive single-agent PTT-936 administered per orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTT-936
Description: Eligible patients will receive single-agent PTT-936 administered per orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTT-936
Description: Eligible patients will receive single-agent PTT-936 administered per orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTT-936
Description: Eligible patients will receive single-agent PTT-936 administered per orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of PTT-936 and anti-PD-1/L1 therapy
Description: Eligible patients will receive combination treatment consisting of PTT-936 administered PO in combination with a Standard of Care (SOC) regimen of an anti-PD-1/L1 agent administered intravenously (IV).
Study: NCT04902677

Intervention type: OTHER
Intervention: Cross-sectional
Description: No intervention
Study: NCT06593496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Reminder
Description: Randomized selection of recruited participants that will receive text messages reminding them to take their blood pressure.
Study: NCT04891562

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: interlimb coordination of the lower limbs and synchronization
Description: 4 sessions (2 descriptive sessions, 2 experimental sessions), each lasting around 60 minutes. The m-ABC2 test, The MBEMA-s, Kids BESTest, interlimb coordination and synchronization investigation (visit 3 and 4)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interlimb coordination of the lower limbs and synchronization
Description: 4 sessions (2 descriptive sessions, 2 experimental sessions), each lasting around 60 minutes. The m-ABC2 test, The MBEMA-s, Kids BESTest, interlimb coordination and synchronization investigation (visit 3 and 4)
Study: NCT06688422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: incentive spirometry
Description: The study will have one intervention group of patients using incentive spirometry in addition to standard of care treatment, including chemo/radiation and immunotherapy maintenance. Patients will use the incentive spirometer 10 times (10 breaths) every hour they are awake. Patients will be asked to start using the incentive spirometer as soon as they are enrolled in the study. Patients will be asked to continue to use incentive spirometry daily, including the duration of chemoradiation and up to three months post-treatment.
Study: NCT06619951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC004 and Itraconazole
Description: A single dose of VC004 was administered in the period 1. and a single dose of VC004 and Itraconazole coadministration in the period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC004 and rifampicin
Description: A single dose of VC004 was administered in the period 1. and a single dose of VC004 and rifampicin coadministration in the period 2.
Study: NCT06685848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemanext ONE system
Description: Hypoxic red blood cells

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional RBCs
Description: Conventional manufactured Red blood cells
Study: NCT06729164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategic and Interactive Signing Instruction
Description: Evidence-based instructional methods guided by cognitive, sociocultural, and linguistic theories that are applied to interventions supporting sign language development among deaf children.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Business-As-Usual Instruction
Description: Teachers will teach business-as-usual without the inclusion of SISI.
Study: NCT06729853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAP-001
Description: a single oral dose of SAP-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAP-001
Description: a single oral dose of SAP-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAP-001
Description: a single oral dose of SAP-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAP-001
Description: a single oral dose of SAP-001
Study: NCT06728202

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A Horizontal Ridge Augmentation in Atrophic Maxillary Ridge
Description: Aiming to enhance bone volume (Quantity) in horizontal maxillary bone defects and density (Quality) , providing a viable solution for implant stability and long-term success.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A Horizontal Ridge Augmentation in Atrophic Maxillary Ridge
Description: Aiming to enhance bone volume (Quantity) in horizontal maxillary bone defects and density (Quality) , providing a viable solution for implant stability and long-term success.
Study: NCT06728943

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ureteral dilatation
Description: Direct semi-rigid ureteroscopy will initially be attempted without endodilatation (KARL STORZ, 43 cm, 6°, 7 Fr.). On failure to advance the semi-rigid ureteroscope through the ureter, intra-ureteric instillation of 20 ml of aminophylline (250 mg/10 mL) through ureteric stent and another trial to pass the same scope will be done after 10 minutes of intra-ureteral aminophylline instillation.
Study: NCT06727994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Providing Genital Hygiene training
Description: After the informed consent of all participants in the study is obtained, pre-test data, Self-Care Power Scale and Genital Hygiene Behavior Scale will be collected face-to-face.~Genital Hygiene training will be given. Reminder training will be given 15 days, 1 month and 2 months after the training, and 1 month after the reminder training, the Self-Care Power Scale and Genital Hygiene Behavior Scale will be re-administered to women as a final test.
Study: NCT06727760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: massage
Description: The mothers in the massage group applied colic massage according to the Educational Colic Massage Checklist twice a day for 15-20 minutes each time for three weeks, when the baby was calm and during colic attacks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: kangroo care
Description: The mothers in the kangaroo care group applied kangaroo care according to the Educational Kangaroo Care Checklist twice a day for three weeks for 15-20 minutes each time when the baby was calm and during colic attacks.